v3.26.1
Additional Information to the Items of Profit or Loss
 12 Months Ended
Dec. 31, 2025
Additional Information to the Items of Profit or Loss [Abstract]  
ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS
NOTE 21:- ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS

 

     Year ended December 31,     
     2025   2024   2023 
a. Research and development expenses:               
  Wages and related expenses  $329   $390   $392 
  Share-based payment   85    45    34 
  Regulatory, professional and other expenses   980    681    719 
  Research and preclinical studies   364    211    101 
  Clinical studies   266    276    254 
  Chemistry and formulations   73    104    141 
                  
      2,097    1,707    1,641 
                  
b. Sales and marketing expenses:               
  Advertising  $155   $367   $576 
  Amazon fees   331    495    1,042 
  Amortization   194    366    486 
  Storage and shipping   112    167    145 
  Management fees   120    120    235 
                  
      912    1,515    2,484 
c. General and administrative expenses:               
  Wages and related expenses   458    507    415 
  Share-based payment   1,103    419    68 
  Professional and directors’ fees   2,823    3,009    2,594 
  Deemed issuance listing expenses   1,410    
-
    
-
 
  Business development expenses   89    108    86 
  Regulatory expenses   222    158    202 
  Office maintenance, rent and other expenses   152    128    110 
  Investor relations and business expenses   114    197    369 
                  
      6,371    4,526    3,844 
d. Other income, net:               
  Loss from sale of property and equipment   
-
    17    
-
 
  Gain on settlement of legal dispute   (464)   
-
    
-
 
  Other income   (26)   
-
    
-
 
  Gain on sale of patent license, net (net of Polyrizon Ltd. holdings sold) (See also Note 24g)   
-
    (1,287)   
-
 
      (490)   (1,270)   
-
 
                  
e. Finance income:               
  Net change in fair value of financial liabilities designated at fair value through profit or loss   (1)   (191)   (2,205)
  Finance income due to cancellation of warrant liability   (1,568)   
-
    
-
 
  Finance income due to revaluation of convertible debentures   (422)   
-
    
-
 
  Interest from loans to related parties and deposits   (207)   (421)   
-
 
  Exchange rate differences   (80)   
-
    (14)
                  
      (2,278)   (612)   (2,219)
f. Finance expenses:               
  Impairment of loan (see note 8c)   5,973    
-
    
-
 
  Issuance expenses   410    
-
    
-
 
  Exchange rate differences   14    18    
-
 
  Losses from remeasurement of investment in financial assets   1,791    305    1,046 
  Finance expense in respect of leases   5    8    9 
  Finance expenses from interest and commissions   6    22    
-
 
                  
     $8,199   $353   $1,055